Human Reproduction, Vol. 14, No. 8, 1949-1952,
August 1999
© 1999 European Society of Human Reproduction and Embryology
Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome
1,51 Departments of Obstetrics and Gynecology, 2 Cardiology, 3 Public Health, Gazi University School of Medicine, Besevler, Ankara, Turkey and 4 Department of Obstetrics and Gynecology, McMaster University School of Medicine, Hamilton, Ontario, Canada
The aim of this study was to examine the echocardiographic profiles of patients with polycystic ovarian syndrome (PCOS). Serum concentrations of follicle stimulating hormone, luteinizing hormone, androstenedione, free testosterone, prolactin, DHEA-SO4 and 17-OH-progesterone, lipid profile (high and low density lipoproteins, triglyceride and total cholesterol) and basal and total insulin after a glucose tolerance test were measured in 35 patients with PCOS and 35 healthy controls matched for body mass index. Doppler, two dimensional M mode echocardiography was performed for the following indices: isovolumetric relaxation time (IVRT), E wave duration time (EVT), A wave duration time (AVT), E wave deceleration time (DT), peak early diastolic flow velocity (PEV), peak late diastolic flow velocity (PAV), E wave velocity time integral (FVI-E), A wave velocity time integral (FVI-A), atrial filling fraction (AFF), ejection fraction (EF), pre-ejection time (PEP), ejection time (ET) and aortic flow velocity time integral (FVI). Androstenedione, free testosterone, low density lipoproteins and cholesterol concentrations were significantly higher in patients with PCOS. There was no difference in basal and total insulin concentrations. IVRT, AVT, FVI-A, AFF, and PEP were higher in patients with PCOS, while PEV, FVI-E, EF, ET, EVT and EVT/AVT were higher in the control group. There was a positive correlation between basal insulin values and IVRT, and between total insulin values and EF. These changes are consistent with a non-restrictive type of diastolic dysfunction and left ventricular stiffness. PCOS may lead to diastolic dysfunction via hyperinsulinaemia and male type dyslipidaemia.
Key words: cardiac flow/male type dyslipidaemia/PCOS
To whom correspondence should be addressed at: Cicekdagi Sok. No: 12/2 GOP, 06700 Ankara, Turkey
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Cascella, S. Palomba, I. De Sio, F. Manguso, F. Giallauria, B. De Simone, D. Tafuri, G. Lombardi, A. Colao, and F. Orio Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome Hum. Reprod., January 1, 2008; 23(1): 153 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Celik, I. Sahin, N. Celik, S. Hascalik, L. Keskin, H. Ozcan, A. Uckan, and F. Kosar Diagnostic potential of serum N-terminal pro-B-type brain natriuretic peptide level in detection of cardiac wall stress in women with polycystic ovary syndrome: a cross-sectional comparison study Hum. Reprod., November 1, 2007; 22(11): 2992 - 2998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. PASQUALI and A. GAMBINERI Polycystic Ovary Syndrome: A Multifaceted Disease from Adolescence to Adult Age Ann. N.Y. Acad. Sci., December 1, 2006; 1092(1): 158 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. DIAMANTI-KANDARAKIS, T. PATERAKIS, and H. A. KANDARAKIS Indices of Low-Grade Inflammation in Polycystic Ovary Syndrome Ann. N.Y. Acad. Sci., December 1, 2006; 1092(1): 175 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Diamanti-Kandarakis, T. Paterakis, K. Alexandraki, C. Piperi, A. Aessopos, I. Katsikis, N. Katsilambros, G. Kreatsas, and D. Panidis Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin Hum. Reprod., June 1, 2006; 21(6): 1426 - 1431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Vural, E. Caliskan, E. Turkoz, T. Kilic, and A. Demirci Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome Hum. Reprod., September 1, 2005; 20(9): 2409 - 2413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.A. Checa, A. Requena, C. Salvador, R. Tur, J. Callejo, J.J. Espinos, F. Fabregues, J. Herrero, and (Reproductive Endocrinology Interest Group of the Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome Hum. Reprod. Update, July 1, 2005; 11(4): 375 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Orio Jr., S. Palomba, L. Spinelli, T. Cascella, L. Tauchmanova, F. Zullo, G. Lombardi, and A. Colao The Cardiovascular Risk of Young Women with Polycystic Ovary Syndrome: An Observational, Analytical, Prospective Case-Control Study J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3696 - 3701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Orio Jr., S. Palomba, S. Di Biase, A. Colao, L. Tauchmanova, S. Savastano, D. Labella, T. Russo, F. Zullo, and G. Lombardi Homocysteine Levels and C677T Polymorphism of Methylenetetrahydrofolate Reductase in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 673 - 679. [Abstract] [Full Text] [PDF]
|
|